Prognostic Value of Hepatic Native T1 and Extracellular Volume Fraction in Patients with Pulmonary Arterial Hypertension

Jiajun Guo,Lili Wang,Jiaqi Wang,Ke Wan,Chao Gong,Xiaoling Chen,Jinghua Guo,Yuanwei Xu,Juan He,Lidan Yin,Shoufang Pu,Bi Wen,Chen Chen,Yuchi Han,Yucheng Chen

DOI: https://doi.org/10.1161/JAHA.122.026254

2022-11-09

Abstract:Background Right heart failure may lead to impaired liver perfusion and venous congestion, resulting in different extents of liver fibrosis. However, whether hepatic tissue deterioration determined by native T1 mapping and extracellular volume fraction using cardiac magnetic resonance imaging is associated with poor outcomes in patients with pulmonary arterial hypertension remains unclear. Methods and Results A total of 131 participants with pulmonary arterial hypertension (mean age, 36±13 years) and 64 healthy controls (mean age, 44±18) between October 2013 and December 2019 were prospectively enrolled. Hepatic native T1 and extracellular volume fraction values were measured using modified Look–Locker inversion recovery T1 mapping sequences. The primary end point was all‐cause mortality; the secondary end point was all‐cause mortality and repeat hospitalization attributable to heart failure. Cox regression models and Kaplan–Meier survival analysis were used to identify the association between variables and clinical outcome. During a median follow‐up of 34.5 months (interquartile range: 25.3–50.8), hepatic native T1 (hazard ratio per 30‐ms increase, 1.22 [95% CI, 1.07–1.39]; P =0.003) and extracellular volume fraction (hazard ratio per 3% increase, 1.18 [95% CI, 1.04–1.34]; P =0.010) values were associated with a higher risk of death. In the multivariate Cox model, hepatic native T1 value (hazard ratio per 30‐ms increase, 1.15 [95% CI, 1.04–1.27]; P =0.009) remained as an independent prognostic factor for the secondary end point. Conclusions Hepatic T1 mapping values were predictors of adverse cardiovascular events in participants with pulmonary arterial hypertension and could be novel imaging biomarkers for poor prognosis recognition. Nonstandard Abbreviations and Acronyms 6MWD 6‐minute walk distance ECV extracellular volume fraction PAH pulmonary arterial hypertension Clinical Perspective What Is New? Hepatic native T1 and extracellular volume fraction values were abnormally increased in patients with pulmonary arterial hypertension more than in healthy volunteers, which may be novel imaging biomarkers for detecting right‐sided heart overload and failure. Increased hepatic native T1 and extracellular volume fraction values were poor prognostic signs for all‐cause mortality, which strengthened the importance of liver function management in patients with pulmonary arterial hypertension during treatment and may add therapeutic benefit. What Are the Clinical Implications? This study shed light on the clinical significance of hepatic T1 mapping assessment in patients with pulmonary arterial hypertension, bringing extra bonus for clinical use of cardiac magnetic resonance imaging and providing a novel method for evaluation of liver involvement in patients with pulmonary arterial hypertension. Pulmonary arterial hypertension (PAH) is a progressive disease leading to right heart failure and death. Therefore, evaluation of right heart function is crucial in both the diagnosis and treatment of PAH. Right heart failure may lead to impaired liver perfusion and venous congestion, resulting in differing extents of liver fibrosis depending on the degree of right heart failure. 1 The extent of liver fibrosis is associated with right atrial pressure, right atrial dilation, and right ventricular (RV) dilation. 2 A retrospective study including 9455 patients with pulmonary hypertension showed that the cumulative incidence rates of nonalcoholic fatty liver disease were significantly higher in patients with pulmonary hypertension (7.3%) than in those without pulmonary hypertension (3.5%; log‐rank test, P <0.001). Furthermore, the former patient group was more likely to develop liver cirrhosis than was the latter group. 3 The gold standard for the diagnosis and staging of liver fibrosis is liver biopsy; however, less invasive and time‐consuming and cost‐effective diagnostic methods such as transient elastography are preferred. 4 , 5 Nevertheless, both liver biopsy and transient elastography can only provide information on liver injury. In previous studies, T1 mapping sequences of car -Abstract Truncated-